Polycystic Ovarian Syndrome: Is It Time to Rename PCOS to HA-PODS?

  • Suvarna Satish Khadilkar
Invited Mini Review


The term polycystic ovarian syndrome (PCOS) came into existence 80 years ago. Pathophysiology of PCOS remains ill understood despite extensive research in this field. It is now accepted that the manifestations of PCOS are not confined to the reproductive dysfunction, and there are endocrine–metabolic implications to PCOS with several consequences to female health. PCOS is a misnomer as ovaries do not contain epithelial cysts, but they are actually antral follicles. Moreover, the name PCOS neither reflects the hyperandrogenism which is essential for diagnosis nor the metabolic derangements. While various authors have expressed the need for change of the name, a suitable new option has not yet been established. This review aims to analyse the current understanding of pathophysiology of PCOS and addresses to the controversies associated with its diagnosis and nomenclature. The name “Hyperandrogenic Persistent Ovulatory Dysfunction Syndrome or HA-PODS” is proposed here to overcome diagnostic pitfalls of previous nomenclature. This new name will help formulate appropriate treatment and promote consistency in research as well. Further categorizations of HA-PODS are also discussed in the article.


PCOS HA-PODS Renaming PCOS Changing name Misnomer 


Compliance with Ethical Standards

Conflict of interest

The author declares that she has no conflict of interest.

Ethical Statements

Author has not received any funds for this paper.

Ethical Approval

This article does not contain any studies with human participants performed by the author.


  1. 1.
    Stein I, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181–5.CrossRefGoogle Scholar
  2. 2.
    Wild RA. Long-term health consequences of PCOS. Hum Reprod Update. 2002;8(3):231–41.CrossRefPubMedGoogle Scholar
  3. 3.
    Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia: Wolters Kluwer Health, Lippincot Williams and Wilkins; 2010. p. 83–103.Google Scholar
  4. 4.
    Dewailly D, Catteau-Jonard S, Reyss AC, et al. Oligo-anovulation with polycystic ovaries (PCO) but not overt hyperandrogenism. J Clin Endocrinol Metab. 2006;91:3922–7.CrossRefPubMedGoogle Scholar
  5. 5.
    National Institutes of Health. Evidence-based methodology workshop on polycystic ovary syndrome (2012). Accessed 31 Jan 2013.
  6. 6.
    Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7.CrossRefGoogle Scholar
  7. 7.
    Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome—the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006;91:781–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456–88.Google Scholar
  9. 9.
    Essah PA, Wickham EP III, Nunley JR, et al. Dermatology of androgen-related disorders. Clin Dermatol. 2006;24(4):289–98.CrossRefPubMedGoogle Scholar
  10. 10.
    Rojas J, Chávez M, Olivar L, et al. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med. 2014; 1–17 Article ID 719050, 17 pages. doi: 10.1155/2014/719050.
  11. 11.
    Marcondes JAM, Hayashida SAY, Barcellos CRG, et al. Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors. Arq Bras Endocrinol Metab. 2007;51(6):972–9.CrossRefGoogle Scholar
  12. 12.
    Baldani DP, Skrgatić L, Goldstajn MS, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Croatian population. Coll Antropol. 2012;36(4):1413–8.PubMedGoogle Scholar
  13. 13.
    Jedel E, Waern M, Gustafson D, et al. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod. 2010;25(2):450–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Ozdemir S, Ozdemir M, Orkemli H, et al. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand. 2010;89(2):199–204.CrossRefPubMedGoogle Scholar
  15. 15.
    Sivayoganathan D, Maruthini D, Glanville JM, et al. Full investigation of patients with polycystic ovary syndrome (PCOS) presenting to four different clinical specialties reveals significant differences and undiagnosed morbidity. Hum Fertil. 2011;14(4):261–5.CrossRefGoogle Scholar
  16. 16.
    Valkenburg O, Steegers-Theunissen RPM, Smedts HPM, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case–control study. J Clin Endocrinol Metab. 2008;93(2):470–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Hahn S, Tan S, Elsenbruch S, et al. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia. Horm Metab Res. 2005;37(7):438–44.CrossRefPubMedGoogle Scholar
  18. 18.
    Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(1):48–53.CrossRefPubMedGoogle Scholar
  19. 19.
    Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2004;82(3):661–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84(1):165–9.PubMedGoogle Scholar
  22. 22.
    Elting MW, Korsen TJM, Bezemer PD, et al. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod. 2001;16(3):556–60.CrossRefPubMedGoogle Scholar
  23. 23.
    Dokras A, Bochner M, Hollinrake E, et al. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol. 2005;106(1):131–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Apridonidze T, Essah PA, Iuorno MJ, et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(4):1929–35.CrossRefPubMedGoogle Scholar
  25. 25.
    Hollinrake E, Abreu A, Maifeld M, et al. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril. 2007;87(6):1369–76.CrossRefPubMedGoogle Scholar
  26. 26.
    Lane DE. Polycystic ovary syndrome and its differential diagnosis. Obstet Gynecol Surv. 2006;61(2):125–35.CrossRefPubMedGoogle Scholar
  27. 27.
    Krymskaia ML. Sclerocystic ovary syndrome: diagnosis and differential diagnosis. Akush Ginekol (Mosk). 1980;9:53–6.Google Scholar
  28. 28.
    Karoshi M, Okolo SO. Commentary: polycystic ovarian disease (PCOD): a misnomer, looking for a new name. Int J Fertil Womens Med. 2004;49:191–2.PubMedGoogle Scholar
  29. 29.
    National Institutes of Health. Panel recommends changing name of common disorder in women. Accessed 31 Jan 2013.
  30. 30.
    Teede H, Gibson-Helm M, Norman RJ, et al. Polycystic ovary syndrome: perceptions and attitudes of women and primary health care physicians on features of PCOS and renaming the syndrome. J Clin Endocrinol Metab. 2014;99:E107–11.CrossRefPubMedGoogle Scholar
  31. 31.
    Carmina E, Wong L, Chang L, et al. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod. 1997;12:905–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Carmina E, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertil Steril. 1999;71:319–22.CrossRefPubMedGoogle Scholar
  33. 33.
    Lobo RA. A disorder without identity: “HCA”, “PCO”, “PCOD”, “PCOS”, “SLS”. What are we to call it?! Fertil Steril. 1995;63:1158–60.PubMedGoogle Scholar
  34. 34.
    Behera M, Price T, Walmer D. Estrogenic ovulatory dysfunction or functional female hyperandrogenism: an argument to discard the term polycystic ovary syndrome. Fertil Steril. 2006;86:1292–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Dunaif A, Bart CJ, Fauser M. Renaming PCOS—a two-state solution. J Clin Endocrinol Metab. 2013;98:4325–8.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Brower M, Brennan K, Pall M, et al. The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS. J Clin Endocrinol Metab. 2013;98:E1967–71.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ledger WL, Atkin SL, Sathyapalan T. Long-term consequences of polycystic ovary syndrome. Green-top guideline no. 33 RCOG November 2014.Google Scholar

Copyright information

© Federation of Obstetric & Gynecological Societies of India 2016

Authors and Affiliations

  1. 1.Room No 129B, First FloorBombay Hospital and Medical Research CentreMumbaiIndia

Personalised recommendations